An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Athersys, Inc. (Nasdaq: ATHX) will hold a conference call on November 10, 2022, at 4:30 PM Eastern Time to discuss its third quarter 2022 financial results. Investors are encouraged to listen via the provided webcast link. Additionally, a replay will be available on the company’s website under the investors' section shortly after the call, lasting until November 17, 2022.
Positive
None.
Negative
None.
CLEVELAND--(BUSINESS WIRE)--
Athersys, Inc. (Nasdaq: ATHX) will be hosting a conference call on Thursday, November 10, 2022, at 4:30 PM Eastern Time to review its third quarter 2022 financial results.
Members of the management team will host the call as follows:
We encourage shareholders to register and listen to the call using the webcast link above. Once registered, you will receive an email containing the toll-free number, a direct entry passcode and a registrant ID. Please send questions you would like management to address in advance of the call to IR@athersys.com.
A replay of the event will be available on the webcast link at www.athersys.com under the investors' section approximately two hours after the call has ended. Shareholders may also call in for on-demand listening approximately three hours after the completion of the call until 11:59 PM Eastern Time on November 17, 2022, by dialing (888) 330-2506 or (240) 789-2712 and entering the conference code 70781.
About Athersys
Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the neurological, inflammatory and immune, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. Investors and others should note that we may post information about the Company on our website at www.athersys.com and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms. It is possible that the postings could include information deemed to be material information. Therefore, we encourage investors, the media and others interested in the Company to review the information we post on our website at www.athersys.com and on our social media accounts. Follow Athersys on Twitter at www.twitter.com/athersys. Information that we may post about the Company on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. You should not place undue reliance on forward-looking statements contained on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
